anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Acupoints of bilateral Tianshu (ST25), which were located according to WHO Standardized Acupuncture Points Location, were used. After sterilizing the skin, needles of the size of 0.35×0.75mm were inserted into ST25 vertically and slowly without manipulation for about 20\~60mm until piercing into the muscle layer. Paired alligator clips of the electric acupuncture (EA) apparatus were attached transversely to the needle holders of bilateral ST25. EA stimulation lasted for 30 minutes with a dilatational wave of 2/15Hz and current intensity of 0.1\~1mA. Participant's abdominal muscle twitching mildly showed the proper dose. Patients were treated once a day, five times a week for continuous 4 weeks.
Atenolol can cause fetal harm when administered to a pregnant woman. Atenolol crosses the placental barrier and appears in cord blood. Administration of atenolol, starting in the second trimester of pregnancy, has been associated with the birth of infants that are small for gestational age. No studies have been performed on the use of atenolol in the first trimester and the possibility of fetal injury cannot be excluded. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.

Neonates born to mothers who are receiving atenolol at parturition or breastfeeding may be at risk for hypoglycemia and bradycardia. Caution should be exercised when atenolol is administered during pregnancy or to a woman who is breast-feeding (see PRECAUTIONS, Nursing Mothers). 

Atenolol has been shown to produce a dose-related increase in embryo/fetal resorptions in rats at doses equal to or greater than 50 mg/kg/day or 25 or more times the maximum recommended human antihypertensive dose *. Although similar effects were not seen in rabbits, the compound was not evaluated in rabbits at doses above 25 mg/kg/day or 12.5 times the maximum recommended human antihypertensive dose *

*Based on the maximum dose of 100 mg/day in a 50 kg patient.
FIELD: organic chemistry, chemical technology, medicine, pharmacy. SUBSTANCE: invention relates to new derivatives of 2-aryl-8-oxodihydropurine of the formula (I)   eliciting selective affinity to BZ w3 -receptor, method for its preparing, pharmaceutical composition and agent comprising thereof and to intermediate compound of the formula (II)   used for preparing derivatives of 2-aryl-8-oxodihydropurine. In compounds of the formula (I) W represents hydrogen atom, lower alkyl group, halogen atom, lower alkoxy- group, amino-group, mono- or di-lower alkylamino-group or unsubstituted phenyl group either phenyl group substituted with trifluoromethyl; X represents hydrogen atom, lower alkyl group, cycloalkyl-lower alkyl group, phenyl-lower alkyl group, lower alkenyl group, carbamoyl group, di-lower alkylcarbamoyl group or group of the formula (Q): -CH(R 3 )CONR(R 1 )(R 2 ) wherein R 1  represents lower alkyl group, lower alkenyl group, cycloalkyl group, cycloalkyl-lower alkyl group or hydroxy-lower alkyl group; R 2  represents lower alkyl group, cycloalkyl group, unsubstituted phenyl group or phenyl group substituted with halogen atom, lower alkoxy- group or hydroxy-group, unsubstituted phenyl-lower alkyl group or substituted with halogen atom, lower alkoxy-group or hydroxy-group; or R 1  and R 2  can be combined with adjacent nitrogen atom with formation if piperidine ring, pyrrolidine ring, morpholine ring or piperazine ring and these rings can be optionally substituted with one or some lower alkyl groups; R 3  represents hydrogen atom, lower alkyl group or hydroxy-lower alkyl group; Y represents hydrogen atom, lower alkyl group, phenyl-lower alkyl group or group of the formula (Q) indicated above; A represents unsubstituted phenyl group or phenyl group substituted with halogen atom, lower alkyl, nitro-group, lower alkoxy-group, trifluoromethyl or hydroxy- group or unsubstituted heteroaryl group taken among pyridyl, thienyl or furyl. In compounds of the formula (II) W represents hydrogen atom, lower alkyl group, halogen atom, lower alkoxy-group, unsubstituted phenyl group or phenyl group substituted with trifluoromethyl; Y 2  represents hydrogen atom, lower alkyl group or phenyl-lower alkyl group; A represents unsubstituted phenyl group or phenyl group substituted with halogen atom, lower alkyl, nitro-group, lower alkoxy-group, trifluoromethyl or hydroxy-group or unsubstituted heteroaryl group taken among pyridyl, thienyl or furyl. Compounds of the formula (I) can be used in anxiolytic agents for treatment of diseases associated with anxiety state. EFFECT: improved preparing method, valuable medicinal properties of compounds. 15 cl, 24 tbl, 323 ex
PURPOSE: The preimplantation genetic testing for aneuploidy (PGT-A) platform is not currently available for small copy-number variants (CNVs), especially those < 1 Mb. Through strategies used in PGT for monogenic disease (PGT-M), this study intended to perform PGT for families with small pathogenic CNVs.
METHODS: Couples who carried small pathogenic CNVs and underwent PGT at the Reproductive and Genetic Hospital of CITIC-Xiangya (Hunan, China) between November 2019 and April 2023 were included in this study. Haplotype analysis was performed through two platforms (targeted sequencing and whole-genome arrays) to identify the unaffected embryos, which were subjected to transplantation. Prenatal diagnosis using amniotic fluid was performed during 18-20 weeks of pregnancy.
RESULTS: PGT was successfully performed for 20 small CNVs (15 microdeletions and 5 microduplications) in 20 families. These CNVs distributed on chromosomes 1, 2, 6, 7, 13, 15, 16, and X with sizes ranging from 57 to 2120 kb. Three haplotyping-based PGT-M strategies were applied. A total of 89 embryos were identified in 25 PGT cycles for the 20 families. The diagnostic yield was 98.9% (88/89). Nineteen transfers were performed for 17 women, resulting in a 78.9% (15/19) clinical pregnancy rate after each transplantation. Of the nine women who had healthy babies, eight accepted prenatal diagnosis and the results showed no related pathogenic CNVs.
CONCLUSION: Our results show that the extended haplotyping-based PGT-M strategy application for small pathogenic CNVs compensated for the insufficient resolution of PGT-A. These three PGT-M strategies could be applied to couples with small pathogenic CNVs.
BACKGROUND: Cervical cancer (CC), closely linked to persistent human papillomavirus infection, represents a major health problem for women worldwide. The objective of this study is to elucidate KIF23's role in the development of CC and its regulatory mechanism.
METHODS: The bioinformatics methods were utilized to extract pyroptosis-associated differentially expressed genes (DEGs) and pivot genes from the GSE9750 and GSE63678 datasets, followed by immune infiltration analysis and quantification of these genes' expression. The effects of kinesin family member 23 (KIF23) were verified through functional experiments in vitro and a mouse xenograft model. The NLPR3 activator, nigericin, was applied for further analyzing the potential regulatory mechanism of KIF23 in CC.
RESULTS: A total of 8 pyroptosis-related DEGs were screened out, among which 4 candidate core genes were identified as candidate hub genes and confirmed upregulation in CC tissues and cells. These genes respectively showed a positive correlation with the infiltration of distinct immune cells or tumor purity. Downregulation of KIF23 could suppress the proliferation, migration, and invasion abilities in CC cells and tumorigenesis through enhancing pyroptosis. Conversely, KIF23 overexpression accelerated the malignant phenotypes of CC cells and inhibited pyroptosis activation, which was blocked by nigericin treatment.
CONCLUSIONS: KIF23 may play an oncogenic role in CC progression via inhibition of the NLRP3-mediated pyroptosis pathway.
PURPOSE: An antidiabetic composition containing capillarisin from an extract of Artemisia capillaris Thunb. is provided. The capillarisin possesses blood-glucose lowering actions and is used as a therapeutic agent for the treatment of diabetes. CONSTITUTION: The antidiabetic composition contains 0.1 to 50% by weight of a compound represented by the formula(1) and pharmaceutically acceptable carriers or excipients. In formula, R1, R2 and R3 are each independently H or acyl (COR) in which R is C1-6 alkyl or substituted aryl. The compound of the formula(1) is capillarisin. For an example, 1kg of Artemisia capillaris Thunb. is extracted with 10L of methanol at room temperature for 24hr, concentrated under reduced pressure and filtrated, then followed by concentration of the supernatant. Then, 20g of fraction is subjected to silica gel column chromatography, washed with 2.5L of chloroform and recrystallized with an acetone/n-hexane solvent to give about 250mg of capillarisin.
Patients in this group will receive continuous lidocaine infusion via closed chest drainage tube. The pulse infusion speed is 1ml / 30min, and the continuous infusion speed was 2ml / h.
The invention discloses a nannochloropsis sp. mutant strain ENN11-2 with a preservation number of CGMCC No.6009, and applications thereof. The nannochloropsis sp. mutant strain ENN11-2 can be used for preparing medicines or health products which are used for preventing and treating cardiovascular and cerebrovascular diseases; for producing or preparing food; for producing baits or animal feed; for producing biofuel and especially biodiesel; for treatment of sewage containing nitrogen and phosphor; for emission reduction of CO2; and for producing long-chain unsaturated fatty acid and especially EPA. Compared with wild strain, growth speed of the nannochloropsis sp. mutant strain ENN11-2 is increased 10%, EPA content is increased 10%, performance is relatively stable, environmental suitability is excellent, disease resistance and insect pest resistance are high, and outdoor validation of the nannochloropsis sp. mutant strain ENN11-2 is realized.
The effects of icosapent ethyl 4 grams per day were assessed in a randomized, placebo-controlled, double-blind, parallel-group study of adult patients (76 on icosapent ethyl, 75 on placebo) with severe hypertriglyceridemia. Patients whose baseline TG levels were between 500 and 2,000 mg/dL were enrolled in this study for 12 weeks. The median baseline TG and LDL-C levels in these patients were 684 mg/dL and 86 mg/dL, respectively. Median baseline HDL-C level was 27 mg/dL. The randomized population in this study was mostly Caucasian (88%) and male (76%). The mean age was 53 years and the mean body mass index was 31 kg/m2. Twenty-five percent of patients were on concomitant statin therapy, 28% were diabetics, and 39% of the patients had TG levels >750 mg/dL.

The changes in the major lipoprotein lipid parameters for the groups receiving icosapent ethyl or placebo are shown in Table 2.

Icosapent ethyl 4 grams per day reduced median TG, VLDL-C, and Apo B levels from baseline relative to placebo. The reduction in TG observed with icosapent ethyl was not associated with elevations in LDL-C levels relative to placebo.
PURPOSE:To obtain the subject formulation useful for preventing, treating diarrhea, etc., promoting the growth, maintaining the health, etc., by culturing Lactobacillus.acidophiluses in a culture medium containing fermentable saccharides as a main carbon source under culture conditions suitable for a facultative anaerobic microorganism and then separating the microbial cell. CONSTITUTION:Lactobacillus.acidophilus PN-RI-2-4 (FERM P-12387) is inoculated into a culture medium containing fermentable saccharides (e.g. glucose) as a main carbon source, cultured under conditions suitable for a facultative fermentable anaerobic microorganism and proliferated and the resultant culture solution is then filtered through a precise filter equipped with an organic membrane having 0.1mum pore diameter and concentrated. A washing liquid is then added to the concentrate and the obtained mixture is filtered and concentrated. The operation is repeated several times to purify the concentrate. Skim milk, sodium glutamate, L-ascorbic acid and L-cysteine are added to the washed microbial cell concentrate and dissolved therein. The pH is regulated to 7 and the concentrate is freeze-dried to afford the objective lactic acid bacterial formulation useful for preventing, treating diarrhea, etc., promoting the growth and maintaining the health.
The present inventors have discovered that porphobilinogen deaminase (PBG), bifunctional purine biosynthetic protein (ADES), and probable transcription factor (PTF1) are essential for normal fungal pathogenicity. Specifically, the inhibition of porphobilinogen deaminase gene expression in fungi abolishes pathogenicity. Inhibition of bifunctional purine biosynthetic protein gene expression in fungi results in drastically reduced pathogenicity. Inhibition of probable transcription factor gene expression in fungi results in drastically reduced pathogenicity. Thus, porphobilinogen deaminase, bifunctional purine biosynthetic protein, and probable transcription factor are useful as targets for the identification of antibiotics, preferably antifungals. Accordingly, the present invention provides methods for the identification of compounds that inhibit the expression or activity of porphobilinogen deaminase, bifunctional purine biosynthetic protein, and/or probable transcription factor. The methods of the invention are useful for the identification of antibiotics, preferably antifungal
Control 'step-up' therapy in the cohort (MONITOR-PsA study). Therapy for the cohort is defined by standard NHS practice following international recommendations and National requirements for the prescription of biologic therapy\[19-22\]. Commonly Initial therapy will be with methotrexate alone (15mg/week rising to 25mg/week as tolerated by week 8 of therapy) unless this is contraindicated. In cases of non-response or intolerance to methotrexate, participants will have an alternative DMARD (most commonly sulfasalazine or leflunomide) added or switched to. In cases of failure of two DMARDs, treatment can be escalated to biologic therapy as per National Institute for Health and Clinical Excellence (NICE) recommendations. If the requisite disease activity is not met or if there are contraindications to biologics, alternative DMARD combinations will be used.
Inclusion criteria: type II diabetic and hypertensive patients who are aged 30 to 70 year-old with HbA1c ≤ 8.0 % and systolic blood pressure ≥ 140 mmHg. Neither ACEI nor ARB is administrated in recent 6 months. None has significant concomitant systemic diseases such as active infection, malignancy, hepatic or significant renal dysfunction at the time of enrollment (i.e. total bilirubin \> 3 mg/dl，ALT \> 2.5 times the upper limit of normal range and creatinine \> 3 mg/dl in our hospital). Information regarding smoking, hypertension, hyperlipidemia as well as history of cardiovascular disease is obtained from all subjects. No other medication will be modified during the study period. After enrollment, patients are assessed to (1) olmesartan (20 mg per day, with titration), (2) life modification/exercise training for 12 weeks. Vascular function and exercise capacity studies, and peripheral blood testing are performed at baseline and at 12- week follow-up. Data are collected as mean ± SD showing comparison between groups by use of 2-sample t test and chi-square analysis for continuous and categorical variables, respectively. Adjust for the HbA1c level will be adjusted using simple adjustment method (ANCOVA or equivalent regression analysis) while doing the data analysis. Changes between baseline and follow-up measurements are assessed by paired t test. The frequencies of adverse effects between groups will also be comparing by 2-sample t test. A p value \<0.05 is defined as statistically significant.
While morphine is the recommended first-line treatment for pain management in patients with acute coronary syndrome, recent studies have raised concerns about its association with adverse outcomes. Morphine has been found to cause delayed antiplatelet effects, decreased ticagrelor absorption, increased platelet reactivity, and compromised efficacy of dual antiplatelet therapy (DAPT). Alternative analgesics, such as lidocaine, fentanyl, and acetaminophen, have begun to emerge as viable alternatives, each with unique mechanisms and potential benefits. Lidocaine is demonstrated to have superior effects in reducing microvascular obstruction and fewer adverse events compared to fentanyl, despite being less effective in pain reduction. Fentanyl, which shows rapid onset and powerful analgesic properties, may interfere with ticagrelor absorption, potentially affecting platelet inhibition. Acetaminophen, a centrally acting analgesic, emerges as a safer alternative with comparable pain relief efficacy and minimal side effects. The results of multiple clinical trials emphasize the significance of customizing pain management approaches to match individual patient profiles and achieving the optimal balance between pain relief and potential adverse outcomes.
<P>PROBLEM TO BE SOLVED: To provide human antibody against respiratory syncytial virus that has at least one CDR (complementarity determining region) originated from at least one murine monoclonal antibody variable heavy chain CDR and at least one murine monoclonal antibody variable light chain, and is MAb1129, and to provide the use of the human antibody against respiratory syncytial virus for preventing and/or treating RSV (respiratory syncytial virus) infection.  <P>SOLUTION: A complementarity determining region (CDR)-grafted human antibody which contains at least one CDR from each variable heavy chain and variable light chain of at least one monoclonal antibody, against the RSV antigen. The monoclonal antibody may be derived from any non-human animal, preferably however, it is derived from a rodent and most preferably it is a murine monoclonal antibody. Preferably, the murine monoclonal antibody is a neutralizing antibody. It is also preferable that the murine antibody is an antibody against RSV F antigen.  <P>COPYRIGHT: (C)2009,JPO&INPIT
A method and computer usable program product for generating meal plans based on a set of nutritional policies. The process determines nutritional requirements specified by a set of nutritional policies in response to receiving a request for a set of meal plans for a set of users. The set of nutritional policies correspond to the set of users. The process identifies a set of potential meal plans in response to determining the nutritional requirements specified by the set of nutritional policies. Each potential meal plan in the set of potential meal plans satisfies all nutritional requirements for the set of nutritional policies. The process generates a listing of ingredients required by the selected meal plan that is unavailable in a current inventory in an amount required by the selected meal plan, in response to receiving a selection of a potential meal plan to form a selected meal plan.
The present invention comprises an analog of the CA 1  A 2  X motif of the protein Ras that is modified by farnesylation in vivo. This CA 1  A 2  X analog inhibits the farnesyl-protein transferase and the farnesylation of certain proteins. Furthermore, this CA 1  A 2  X analog differs from most compounds previously described as inhibitors of farnesyl-protein transferase in that it does not have a thiol moiety. The lack of the thiol offers unique advantages in terms of improved pharmacokinetic behavior in animals, prevention of thiol-dependent chemical reactions, such as rapid autoxidation and disulfide formation with endogenous thiols, and reduced systemic toxicity. The compound of the instant invention also incorporates a cyclic amine moiety in the A 1  position of the motif. Further contained in this invention are chemotherapeutic compositions containing this farnesyl transferase inhibitor and methods for its production.
AIM: Van der Zee (VdZ) described a technique to elongate the oesophagus in long-gap oesophageal atresia (LGOA) by thoracoscopic placement of external traction sutures (TPETS). Here, we describe our experience of using this technique.
METHOD: Retrospective review of all LGOA + / - distal tracheo-oesophageal fistula (dTOF) cases where TPETS was used in our institutions. Data are given as medians (IQR).
RESULTS: From 01/05/2019 to 01/03/2023, ten LGOA patients were treated by the VdZ technique. Five had oesophageal atresia (Gross type A or B, Group 1) and five had OA with a dTOF (type C, Group 2) but with a long gap precluding primary anastomosis. Age of first traction procedure was Group 1 = 53 (29-55) days and Group 2 = 3 (1-49) days. Median number of traction procedures = 3; time between first procedure and final anastomosis was 6 days (4-7). Four cases were converted to thoracotomy at the third procedure. Three had anastomotic leaks managed conservatively. Follow-up was 12-52 months. All patients achieved oesophageal continuity and were orally fed; no patient required an oesophagostomy.
CONCLUSION: In this series, TPETS in LGOA facilitated delayed primary anastomoses and replicated the good results previously described but, in addition, was successful in cases with dTOF. We believe traction suture placement and tensioning benefit from being performed thoracoscopically because of excellent visualisation and the fact that the tension does not change when the chest is closed. Surgical and anaesthetic planning and expertise are crucial. It is now our management of choice in OA patients with a long gap with or without a distal TOF.
After Baseline and after follow-up of at least 3 month, patients with AF lasting longer than one minute detected by pacemaker will come to this group /stage (Atrial Pacing). At this stage, the pacing mode and the lower rate of pacemaker will be set as DDD and 70/60 bpm respectively, to perform relatively high-rate atrial pacing. Except for beta-blockers digoxin, and CCB to control heart rate, anti-arrhythmic drugs (AAD) will not be prescribed. After follow-up of at least 3 month, patients with AF lasting longer than one minute detected by pacemaker will go to next group/stage (AAD, Step1).
For those who have kidney failure and are managed conservatively without dialysis, symptoms are often prevalent, multiple, and troublesome. They interfere with quality of life, reduce wellbeing, and can affect family carers too. Symptoms can sometimes be difficult to manage, and-for professionals-they are often hard to assess and not always amenable to management with medications appropriate for use in kidney failure. Fatigue is one of the most common symptoms; alongside a general overview of symptoms in this population, we include a more detailed discussion of this often-neglected symptom. The solutions to the main symptoms experienced by those with kidney failure managed conservatively without dialysis lie in detailed assessment and monitoring of symptoms, working as a multi-disciplinary team to the maximum to draw on the full range of skills and expertise, and use of non-pharmacological, as well as pharmacological, approaches. Both nephrology and palliative care skills and expertise are important to optimise the recognition, assessment, and management of symptoms. There are few published descriptions of models of conservative kidney management (CKM) or supportive kidney care and there is a lack of evidence to suggest which model is most effective. We therefore consider the evidence on optimal models of CKM and make suggestions for best practice.